Oncology

medical specialties

The week's innovation in oncology, published every Sunday for the week before: new technology, AI tools, devices, FDA decisions on new technology and new ways of delivering care, every item linked to its sources.

FDA approves durvalumab with enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; camrelizumab lifts event-free survival

An infusion bag of amber fluid hanging from a single upright IV pole whose top bends into two curved hooks like a shepherd's crook, with a drip chamber, roller clamp and capped tubing below.

The Food and Drug Administration (FDA) approved durvalumab with enfortumab vedotin-ejfv on Nov. 13 for muscle-invasive bladder cancer in adults ineligible for or who refused cisplatin-based chemotherapy, based on the VOLGA trial.

The American Cancer Society (ACS) updated its prostate cancer screening guideline, last published in 2010, a phase 2 trial reported longer event-free survival with perioperative camrelizumab in head and neck cancer, and a phase 3 trial found a weekend dasatinib holiday noninferior in chronic myeloid leukemia.

  • FDA Nov 13, 2026
    The Food and Drug Administration (FDA) approved neoadjuvant durvalumab with enfortumab vedotin-ejfv, followed by adjuvant durvalumab after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or refused cisplatin-based chemotherapy. VOLGA randomized 695 patients 1:1:1, including a cystectomy-alone arm. Median event-free survival, the major efficacy outcome, was not reached with the combination versus 12.1 months with cystectomy alone (hazard ratio 0.51, 95% CI 0.38 to 0.67). The overall survival hazard ratio was 0.58 (95% CI 0.40 to 0.83).
    Source: FDA
  • FDA Nov 10, 2026
    The Food and Drug Administration (FDA) approved pimicotinib (Pimjetmi) on Nov. 10 for adults with symptomatic tenosynovial giant cell tumor in whom surgical resection could potentially worsen functional limitations, according to OncLive and CancerNetwork. In part 1 of the randomized phase 3 MANEUVER trial, 94 patients were assigned 2:1 to pimicotinib 50 mg once daily or placebo for 24 weeks, and the objective response rate at week 25 was 54.0% versus 3.2%, CancerNetwork reported. The most common adverse reactions included pruritus, rash, face edema, periorbital edema, fatigue, nausea, headache and peripheral edema.
  • Guidelines Nov 12, 2026
    The American Cancer Society (ACS) guideline, published Nov. 12 in CA: A Cancer Journal for Clinicians, recommends PSA-based screening every two years for average-risk men aged 50 to 69 and annual screening from age 45 to 69 for Black men and for men with a first-degree relative diagnosed before 65 or multiple first-degree relatives with prostate cancer. Men with a confirmed elevated PSA should be offered MRI and/or a validated biomarker to guide biopsy decisions, the ACS said. Screening is not recommended for men aged 75 and older. The previous ACS guideline was published in 2010.
  • Research Nov 12, 2026
    The phase 2 CAMORAL trial at four academic hospitals in China, published Nov. 12 in JAMA Oncology, randomized 125 patients with locally advanced head and neck squamous cell carcinoma to neoadjuvant camrelizumab with albumin-bound paclitaxel and carboplatin followed by surgery, risk-adapted adjuvant therapy and maintenance camrelizumab, or to upfront surgery with risk-adapted adjuvant therapy. Two-year event-free survival, the primary end point, was 77.8% versus 46.1% (hazard ratio 0.34, 95% CI 0.17 to 0.68), and two-year overall survival was 92.0% versus 69.1% (hazard ratio 0.25, 95% CI 0.10 to 0.64). Grade 3 or higher adverse events occurred in 79.4% versus 56.5%.
  • Research Nov 13, 2026
    The phase 3 DasaHIT trial of the German Chronic Myeloid Leukemia Alliance, published Nov. 13 in the Journal of Clinical Oncology, assigned 289 eligible patients to continuous dasatinib or five days on and two days off. Major molecular response at 24 months, coprimary with a cumulative toxicity score, was 81% with continuous and 78% with intermittent dosing, within the prespecified 15% noninferiority margin. Grade 2 to 4 toxicities did not differ significantly. It was 24% lower, failing noninferiority, in second- or later-line patients. In a post hoc analysis, pleural or pericardial effusions occurred in 16% versus 8%, respectively.

Latest news

Tagged oncology, from the daily briefing

  1. Phase 3 PACE-NODES trial reports early adverse events for pelvic nodal plus prostate SBRT versus prostate-only SBRT
  2. REFUEL trial tests a 12-week multidisciplinary program for persistent fatigue in lymphoma survivors
  3. ALNEO phase 2 trial reports neoadjuvant alectinib before surgery in resectable stage III ALK-positive lung cancer

See all the latest news

Earlier weeks

The weekly podcast

Each Sunday's oncology innovation roundup as a short audio briefing, read by AI voices. Play any episode here, or follow the show in any podcast app.

In any podcast app, add the feed: https://feeds.transistor.fm/physician-in-the-loop-oncology